Texas Medical Center
jtyustei@texaschildrens.org
Address
Houston, TX 77030
Research Laboratory
Jason T. Yustein, MD, PhD
Associate Professor, Department of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine
Education
| School | Education | Degree | Year |
|---|---|---|---|
| Johns Hopkins School of Medicine | fellowship | Hematology-Oncology | 2008 |
| Johns Hopkins University School of Medicine | residency | Pediatrics | 2005 |
| Case Western Reserve Univ. School of Medicine | medical school | Doctor of Medicine | 2002 |
| Case Western Reserve University | university | Doctor of Philosophy | 2002 |
About
Dr. Jason Yustein is Director of the Faris D. Virani Ewing Sarcoma Center and a member of the Bone Tumors Program. His clinical interests are focused on pediatric sarcomas, such as Ewing sarcoma.
Dr. Yustein is one of the experts participating in the New Agents for Ewing Sarcoma Task Force formed in 2019 by the Children's Oncology Group Bone Tumor Committee. The mission of the task force is to evaluate and prioritize new agents for incorporation into clinical trials for metastatic and relapsed Ewing sarcoma.
Board Certifications American Board of Pediatrics American Board of Pediatrics – Hematology/Oncology
Organization
| Organization Name | Role |
|---|---|
| American Academy of Pediatrics (AAP) | Member |
| American Society for Pediatric Hematology/Oncology (ASPHO) | Member |
Research Statement
Dr. Jason Yustein’s research interests include furthering the biological, molecular and genetic understanding of pediatric sarcomas, including osteosarcoma and Ewing’s sarcoma, through the formation of novel model systems that will lead to the discovery of new therapeutic targets and subsequent development of new treatment interventions. For example, Dr. Yustein is utilizing osteoblast-specific expression of an oncogenic p53 mutant to form a novel, applicable transgenic mouse model of metastatic osteosarcoma, a condition that has a particularly poor prognosis. Such models will allow for further understanding of critical genes and microRNAs involved in sarcoma development, progression and metastasis and utilized as preclinical models for therapeutic testing and efficacy.
Selected Publications
Ghosal G, Yustein JT. GEWS-FLI1 Regulates Genotoxic Stress Response in Ewing Sarcoma, J Cancer Biol Res. 2015 May 6; 3(2): 1063.
Roos A, Satterfield L, Zhao S, Fuja D, Shuck R, Hicks JM, Donehower LA, Yustein JT. Loss of Runx2 sensitizes osteosarcoma to chemotherapy-induced apoptosis, accepted, British Journal of Cancer. (Corresponding author)
Rao P H, Kurenbekova L, Rainusso N, Trucco M, Allen-Rhoades W, Borra V P, Man T, Donehower LA , Yustein JT. Co-Amplification of Myc/Pvt1 and Homozygous Deletion of Nlrp1 Locus are the Frequent Genetics Changes in Mouse Osteosarcoma, accepted, Genes Chromosomes and Cancer. (Corresponding author)
Allen-Rhoades W, Kurenbekova L, Satterfield L, Parikh N, Fuja D, Shuck RL, Rainusso N, Trucco M, Barkauskas DA, Jo E, Ahern C, Hilsenbeck S, Donehower LA, Yustein JT. Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma. Cancer Med. 2015 Jul; 4(7):977-88.
Zhao S, Kurenbekova L, Gao Y, Roos A, Creighton CJ, Rao P, Hicks J, Man TK, Lau C, Brown AM, Jones SN, Lazar AJ, Ingram D, Lev D, Donehower LA, Yustein JT. NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma. Oncogene. 2015 Jan 12.
Rainusso N, Wang LL, Yustein JT. The adolescent and young adult with cancer: state of the art — bone tumors. Curr Oncol Rep. 2013 Aug; 15(4):296-307.
Wu G, Yustein JT, McCall MN, Zilliox M, Irizarry RA, Zeller K, Dang CV, Ji H. ChIP-PED enhances the analysis of ChIP-seq and ChIP-chip data. Bioinformatics. 2013 May 1; 29(9):1182-9.
Ke S, Wang W, Qiu X, Zhang F, Yustein JT, Cameron AG, Zhang S, Yu D, Zou C, Gao X, Lin J, Yallampalli S, Li M. Multiple target-specific molecular agents for detection and image analysis of breast cancer characteristics in mice. Curr Mol Med. 2013 Mar; 13(3):446-58.
Awad O, Yustein JT, Shah P, Gul N, Katuri V, O’Neill A, Kong Y, Brown ML, Toretsky JA, Loeb DM. High ALDH activity identifies chemotherapy-resistant Ewing’s sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS One. 2010 Nov 11; 5(11):e13943.
Yustein JT, Rednam S, Bertuch AA, Goss JA, Brandt ML, Eldin K, Lu X, Hicks J. Abdominal undifferentiated small round cell tumor with unique translocation (X;19)(q13;q13.3). Pediatr Blood Cancer. 2010 Jul 1; 54(7):1041-4.
Language
Latest Videos
Ribbon Cutting for Faris D. Virani Ewing Sarcoma Center at Texas Children's Cancer Center
Q&A: What is Ewing sarcoma?
* Texas Children's Hospital physicians' licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician's office and were not verified by Texas Children's Hospital.